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Abstract 
Introduction  
HIV viral load testing is the preferred monitoring approach for HIV infected patients on combination 
antiretroviral therapy (cART) as it is more sensitive than CD4 count and clinical monitoring.   In 
resource limited settings, timely plasma separation and transportation to testing laboratories is a 
major barrier to the access of HIV viral load testing.  The 2015 World Health Organisation guidelines 
recommend that cART should be initiated in all adults and children living with HIV regardless of 
disease stage or CD4 count, thereby escalating the demand for HIV viral load testing.  Potential 
solutions to expand implementation and scale up of viral load testing in low and middle income 
countries are whole blood testing through point of care (POC) viral load assays or dried blood spots 
(DBS) collected at the health facility.  Utilization of whole blood instead of plasma would simplify 
sample collection, storage and transportation requirements and be cost effective.  However, the 
paucity of studies comparing whole blood HIV viral load across different test platforms, especially in 
the correct classification of virological failure, has resulted in the lack of a standardised 
programmatic approach to whole blood viral load testing.   
Methods  
We evaluated four HIV whole blood viral load test methods namely Alere q HIV-1/2 POC, Abbott 
RealTime HIV-1 DBS original and updated protocols, and Roche CAP/CTM DBS free virus elution (FVE) 
protocol, against the standard of care, plasma viral load, on 299 samples across the viral load 
spectrum from South African patients on cART.  Virological failure was defined at >1000 copies/ml.  
Proportions of correct classification of virological failure and overall correlation with plasma were 
used for evaluating each method’s performance.   
Results 
Alere q, Abbott original and updated, and Roche FVE correctly classified virological failure in 61%, 
89%, 87% and 76% of all samples tested respectively.  The performance varied across plasma viral 
load categories.  Alere q showed good correlation above plasma viral load of 1000 copies/ml, with 
correct classification of virological failure in 100% of samples.  However, below the plasma threshold 
of 1000 copies/ml, Alere q demonstrated significant over-quantification, resulting in reduced 
specificity and upward misclassification of virological failure in 39% of all samples tested.  Abbott 
original and updated also had good sensitivity of 98% and 91% respectively and the best overall 
correlation with plasma (r2 = 0.76 and 0.72 respectively), but there was upward misclassification in 
10% and 8% of samples tested respectively.  Roche FVE had the best specificity of 99% but with 
significantly reduced sensitivity of 53%, especially between 1000–10,000 copies/ml of plasma, 
resulting in downward misclassification in 24% of all samples tested. Greatest variability between 
the different testing methods was seen when plasma viral load was 40-1000 copies/ml.   Correlation 
was best for all whole blood viral load assays at >10,000 copies/ml.   
Conclusion 
The key finding highlighted by this study is the great variability between the different whole blood 
test methods.  Various factors influence the ability to quantify whole blood HIV viral load such as 
input volume used in each assay vary, sample treatment/processing (DBS versus fresh blood samples 
versus FVE), extraction (RNA selective, total nucleic acid extraction), amplification target and 
detection methods are different for each of the platforms tested.  Based on our study, Alere q and 
Abbott DBS need to raise their whole blood threshold for virological failure in order to reduce 
upward misclassification and Roche FVE needs to achieve better sensitivity around its limit of 
detection.  Receiver operating characteristic curve analysis can be used to determine the optimum 
threshold of virological failure for each assay. 
 
 
5 
 
Chapter 1:  Literature Review 
HIV/AIDS remains one of the world's most significant public health challenges, particularly in low and 
middle income countries(1).  In 2015, there were 36.7 million (34–39.8 million) people living with 
HIV(2).  Sub-Saharan Africa, especially southern Africa, has the highest global burden of HIV (70%)(3).  
As of December 2015, 17 million people living with HIV were accessing combination antiretroviral 
therapy (cART), an increase from 15.8 million in June 2015(2).  In sub-Saharan Africa itself, 10.3 
million people were accessing cART, with treatment coverage increasing from 24% in 2010 to 54% in 
2015(4).  HIV prevalence is therefore increasing worldwide because people on cART have increased 
life expectancies(3). 
 
Monitoring individuals receiving cART is important to ensure successful treatment (virological 
suppression), identify adherence problems and treatment failure(5).  The 2016 World Health 
Organisation (WHO) consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection recommend HIV viral load testing as the preferred monitoring tool for 
diagnosing and confirming the failure of cART as it is more sensitive and an earlier indicator of 
treatment failure than CD4 count or clinical monitoring, thereby reducing the accumulation of drug-
resistance mutations and improving clinical outcomes(6).  Virological failure as defined by WHO is 
plasma HIV RNA > 1000 copies/ml based on two consecutive viral load measurements three months 
apart with adherence support after at least six months of starting a new cART regimen(7). 
 
Identifying treatment failure early enables patient adherence counselling and may enable patients to 
stay on first line cART longer, thereby avoiding unnecessary switches to more expensive second line 
regimens(8). Viral load testing also enables clinicians to switch failing patients earlier to second and 
third line regimens, before the accumulation of drug resistance mutations, thereby reducing the 
spread of highly resistant virus(8). 
 
The South African National guidelines released in 2014 also advocate use of HIV viral load for 
monitoring treatment success and early identification of treatment failure  and advise to consider 
switching patients on the first line regimen if the patient has experienced virological failure on at 
least two occasions two months apart despite good adherence(9).  After initiating cART, monitoring 
with viral load is recommended at month six, one year on cART and then annually(9). 
 
In South Africa the threshold for initiation of cART rose to CD4 count ≤500/μl and the prevention of 
mother to child transmission (PMTCT) programme adopted the B+ approach, which entitles every 
pregnant and breastfeeding woman to lifelong cART regardless of CD4 count or clinical staging, 
which was implemented in January 2015 (9).  The department of health has a 2020 target of having 
90% of people tested for HIV and 90% of those eligible for treatment on treatment, with at least 90% 
of those on treatment virally suppressed which is in line with the UNAIDS goal to help end the AIDS 
pandemic(9, 10).   
 
In the WHO guideline on when to start cART and on pre-exposure prophylaxis for HIV, released in 
September 2015, it is recommended that cART should be initiated in all adults and children living 
with HIV at any CD4 cell count, with evidence for both public health and individual benefit from the 
START and TEMPRANO trials published in 2015(11-13).  The South African Minister of Health, Dr. Aaron 
Motsoaledi announced in the budget speech in 2016 that from September 2016 everyone with HIV 
will be eligible for cART irrespective of CD4 count(14). These encouraging changes mean greater 
access to cART with more patients receiving care and monitoring, leading to reduced morbidity and 
mortality.   With an expanding number of HIV infected patients on cART, there is a greatly increased 
demand and workload on laboratories in producing HIV viral load results accurately and timeously.  
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Plasma HIV viral load is the current universal standard of care using ethylenediaminetetraacetic acid 
(EDTA) tubes or plasma preparation tubes (PPT)(15). Plasma viral load determination requires venous 
blood collection, processing (centrifuging) of that blood to obtain plasma within a certain timeframe, 
cold chain and storage of specimens by trained personnel (Table 1)(16, 17).   Generating plasma 
samples requires trained phlebotomists and electricity in health care facilities to power the 
centrifuges(15).  Most cART programmes in resource limited settings still do not have access to viral 
load testing and continue to rely on clinical and immunological monitoring(5). This restricted access 
to viral load testing has been identified as a key reason for the lower than expected rates for 
switching cART regimens in resource limited settings(5).  Its availability has been severely restricted 
because of prohibitively high costs, complex specimen collection, efficient transportation and 
storage requirements and the need for well-established laboratory infrastructure and well-trained 
personnel(17).   
 
Factors which could affect HIV RNA stability include the effects of cellular fractions, pre-processing 
storage temperature, and time delays to processing(18).  In a study on HIV RNA stability, HIV RNA 
levels were stable for up to 30 hours after collection when stored at either room temperature (mean 
standard deviation (SD) = 0.101 log10 units) or at 4°C (mean SD = 0.102 log10 units) as plasma or as 
EDTA-anticoagulated whole blood (mean SD = 0.109 log10 units)
(18).  Commercial viral load assays 
recommendations for specimen storage are as follows:  freshly drawn specimens (whole blood) may 
be held at 15-30°C for up to 6 hours or at 2-8°C for up to 24 hours, prior to centrifugation(19).  After 
centrifugation, plasma may be stored at 15-30°C for up to 24 hours or at 2-8°C for up to 5 days(19).   
In a systematic review by Bonner et al in 2014, they found extended HIV RNA stability compared to 
the recommended times and temperatures, however this is based on nine studies done in Europe 
and U.S. with most participants being cART naive, therefore they recommend further studies in low 
resource settings and warmer climates as well as assessing HIV RNA stability in patients with low 
viral load close to the virological failure threshold of 1000 copies/ml(15). 
 
Table 1.  HIV RNA stability times at different temperatures(17) 
 
Temperature 37⁰C  15-30⁰C  4⁰C -20⁰C -70⁰C 
Whole blood (EDTA) 6 hours 6 hours 24 hours N/A N/A 
Plasma 24 hours 24 hours 5 days 1 year 5 years 
DBS 1-2 weeks 1-2 weeks 2-52 weeks 3-36 months 1 year 
Table 1 is an excerpt from the WHO technical and operational considerations for implementing HIV viral load 
testing and includes a summary of published studies and manufacturer recommendations for time of transport 
and storage at various conditions for plasma, whole blood and DBS specimens for HIV viral load testing
(17)
.  
N/A= not applicable. 
 
In rural areas which are far from the centralised laboratories, sample transport networks do not 
function well resulting in long delays reaching the laboratory with potential degradation of sample, 
poor accuracy of results, long turnaround times and loss to follow up of patients.  Such restrictive 
transportation and storage requirements greatly limits access to viral load testing to only those in 
close proximity to national or regional laboratories(15).    
 
Several solutions have been sought to improve access to viral load testing globally.  The price per 
viral load test can range widely (U.S. 10-60 dollars) depending on the manufacturer and country(17). 
Several manufacturers have now committed to regional agreements in which reduced pricing for 
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viral load reagents may be obtained for as low as U.S. 10.50 dollars per test(17).  The 2016 WHO 
consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 
advocate dried blood spots (DBS) using venous or capillary whole blood as a tool to increase access 
to viral load testing in settings where logistical, infrastructural or operational barriers prevent 
routine viral load monitoring using plasma specimens(6).  New platforms for high volume testing are 
also becoming available, allowing cost effective consolidation of testing in high volume centres (e.g. 
super-laboratories)(16).  A much anticipated alternative solution to expand access would be to 
decentralise testing by using point of care (POC) technologies that will enable testing in remote 
health care facilities(8).  Differential care models proposed such as viral load informed differentiated 
care is a cost effective means of tailoring care so that those with suppressed viral load visit the clinic 
less frequently and attention is focussed on those with unsuppressed viral load to promote 
adherence and timely switching to a second line regimen(20).     
 
Whole blood testing in the form of DBS has been evaluated in several studies as a method to greatly 
expand HIV early infant diagnosis and viral load access in rural settings(21).  Utilization of DBS samples 
for viral load will greatly simplify the transport of samples, providing enhanced stability and ease of 
use for health care workers and is also cost effective(16).  DBS remains stable over extended time and 
temperature periods, often making this the only practical transport option in remote areas(15).  In 
South Africa DBS is routinely used for infant HIV diagnostic PCR testing(22). DBS is simple to collect 
and prepare and stable at room temperature therefore easy to transport with no need for cold chain 
or worry about transportation delays.  A drop of blood can be obtained in the field from a finger or 
heel prick, applied to a piece of filter paper, air-dried, and stored until measurement of HIV viral 
load(23).  The reduction in required materials, less biological waste production and no need of highly 
skilled personnel at clinic level, decreases costs considerably in comparison to standard blood 
collection methodologies by venipuncture(24).  Transport associated risks are minimal as DBS cannot 
break or leak and can be sent at ambient temperatures, without the need for cold packs or 
expensive dry ice(24).  Using existing networks for early infant HIV diagnosis, they can be transported 
to a regional or national laboratory with results subsequently returned to the clinic by, for example, 
mobile phone text messaging(20). 
 
An appealing solution to improve access is to bring the testing closer to the site of patient care, 
thereby minimising the time to obtain a result and expedite clinical decision making (25, 26). With the 
goal of improving the accessibility and affordability of cART, there is a growing demand for simple, 
affordable, reliable and quality assured POC diagnostics for use in resource limited settings(16).  POC 
viral load testing would reduce the need for expensive laboratory infrastructure and highly skilled 
laboratory workers, and also could lower the cost of testing(16).  Rapid, reliable and affordable POC 
viral load, with minimal equipment and training requirements, would have a major impact on 
treatment outcomes by facilitating timely detection of virological failure and swift clinical decision 
making as well as reduce loss to follow up(27, 28).  There are several POC technologies in the pipeline 
for HIV viral load which are being evaluated in both laboratory and field conditions(8). 
 
POC testing will not be a magic bullet and will most likely complement and not replace conventional 
testing platforms(29). The appropriate mix of high-volume laboratories and POC testing will be 
country specific, and will depend on such factors as the urban/rural split of the country, the 
expected volume of testing and the ability to effectively transport samples between collection sites 
and laboratories and ensure the efficient return of laboratory results back to collection sites(16). 
Realistically, it also will depend on the comparative all-in cost of centralised versus decentralised 
testing(16).  Improved access likely will be achieved through a mix of diagnostic services in most 
countries that combines high volume laboratories in high density areas, and lower volume POC 
testing in less densely populated regions(16).  POC implementation will still require training of staff, 
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implementation of quality control mechanisms, and operational research to assess POC performance 
and the benefits of POC testing over conventional testing(29). 
 
Although DBS is routinely used for early infant diagnosis, its use for viral load testing has not become 
routine practice.  This is due to the interpretation of whole blood viral load in comparison to plasma 
and the lack of standardization and previous guidelines.  The utilisation of DBS for HIV viral load 
testing has been evaluated by several studies including systematic reviews(21).  However, the number 
of studies and sample sizes are small, different methodologies, protocols and viral load thresholds 
were used, and mostly tested in a controlled laboratory environment and not in the field.  This has 
resulted in a lack of standardization and therefore implementation into programmes.   
 
The studies do characterise the intrinsic properties of whole blood HIV viral load testing which 
should guide further studies in optimization and selection of a threshold for virological failure.  
Technical issues related to the adaptation of viral load assays to DBS, especially with respect to 
sensitivity (limit of detection), specificity (cell free RNA in plasma versus cell associated DNA or RNA 
in whole blood), and assay method, affect the interpretation of a viral load result from DBS(30).  There 
are two sides of a coin to whole blood HIV viral load testing affecting both sensitivity and specificity.  
Sensitivity can be reduced by the smaller volumes used in comparison to routine plasma viral load 
testing especially at lower viral loads.  Specificity can also be reduced as whole blood measures both 
extracellular HIV RNA and intracellular HIV RNA and proviral DNA while plasma measures only 
extracellular HIV RNA.  This has an impact on determining the optimum threshold for classification of 
virological failure. 
 
Reduced sensitivity of DBS compared to plasma is caused by reduced input copy number from DBS 
related to limitations on the volume of blood per DBS (50-75ul) and number of DBS (usually not 
more than two) that can be subjected to nucleic acid extraction, reduced efficiency of nucleic acid 
extraction, and the presence of interfering substances in DBS (such as haemoglobin) that can inhibit 
amplification or detection(30).  Reduced specificity of DBS compared to plasma results from cell 
associated HIV nucleic acids(30).  Unlike a plasma HIV viral load which measures only cell free HIV 
RNA, a DBS viral load also measures proviral DNA as well as cell associated RNA, potentially leading 
to false positive results when using DBS(21).  Cell associated HIV nucleic acids may be in the form of 
proviral or unintegrated DNA, transcribed spliced/unspliced RNA or viral RNA in particles bound to 
cells such as platelets(30).  The relative contribution of each type of nucleic acid is likely to vary 
between patients depending on clinical parameters and treatment status(30).  The degree to which 
DNA can impact the viral load result will depend on how much DNA is present in the extracted 
nucleic acid, and by the detection technology used for quantitation (real time PCR is non-specific, 
while nucleic acid sequence based amplification (NASBA) is specific for RNA)(30).  Depending on the 
total amount of nucleic acid present in these compartments relative to viral RNA in plasma, and on 
the extraction and amplification procedure of the assay, the viral load from DBS can be higher than 
the corresponding value obtained from plasma(30).  This effect is most prominent at low or 
undetectable levels of plasma RNA, since decay of nucleic acid in latently infected cells is slower than 
that of plasma virus(30).  When plasma viral RNA is suppressed to below the detection limit of the 
assay, this can result in a “false positive” result from DBS since proviral DNA and spliced RNA may 
continue to be detectable in latently infected T cells(30).  This can contribute to low specificity and 
lead to misclassification of patients with suppressed plasma virus as experiencing treatment 
failure(30). 
 
The extent to which DNA and RNA will contribute to the signal in a viral load assay is dependent on 
the selectivity of the extraction method and the specificity of the detection method used(30). 
Extraction methods that are selective for RNA (closer correlation with plasma) include RNA-specific 
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nucleic acid extraction, DNAse pretreatment to remove DNA, and virus particle elution(8).  
BioMérieux uses total nucleic acid extraction with NASBA while Abbott uses RNA-selective extraction 
with real time PCR (both methods close to plasma RNA)(8). Roche uses total nucleic acid extraction 
followed by real time PCR (RNA and DNA copy number) and has also validated a “free virus elution” 
(FVE) method with results closer to plasma RNA(8, 31).  Viral load tests using fresh whole blood will 
have the same issues with cell associated RNA and proviral DNA as DBS, unless a plasma separation 
step is included(8).  For non selective assays, the contributions of cell associated RNA and proviral 
DNA can add a “baseline” to the plasma viral load detected below 3000–5000 copies/ml (plasma 
RNA dominates the assay above 5000 copies/ml)(8).  These relative contributions can vary for treated 
versus untreated patients and healthy versus immunocompromised patients(8). 
 
There is also a difference between venous and capillary blood.  Capillary blood is easier to collect by 
finger or heel prick than venous blood which requires phlebotomy however there is more variability 
in volume spotted and presence of interfering or diluting fluids in capillary blood(30).  Capillary blood 
has been shown to be feasible and performs comparably to venous blood in several studies (32-34). 
 
In a systematic review of dried fluid spots for HIV viral load and resistance genotyping by Hamers et 
al in 2009, the data indicated that HIV viral load determination by DBS is feasible, yielding 
comparable test performances, even after storage(35).  Limitations include reduced analytical 
sensitivity resulting from small volumes (approximately 3.5 log10 copies/ml at 50ul sample volume), 
nucleic acid degradation under extreme environmental conditions, impaired efficiency of nucleic 
acid extraction, potential interference of archived proviral DNA and the excision of spots from the 
filter paper cards in high volume testing(35).  They indicate that consistently improved analytical 
sensitivity is needed for routine application of DBS for the monitoring of drug resistance in 
individuals receiving cART, particularly at the onset of treatment failure(35).  They recommended that 
further studies should be directed towards further optimization and standardization of assay 
protocols, sensitivity and precision, nucleic acid stability under extreme storage conditions, and that 
comparative studies of test performance of various commercial viral load assays are warranted(35). 
 
In a more recent systematic review of the use of DBS for monitoring HIV viral load published by Smit 
et al in March 2014, they included thirteen peer reviewed publications and found that depending on 
the technology and the viral load distribution in the study population, the percentage of DBS 
samples that are within 0.5 log10 of viral load in plasma ranged from 52–100%
(21). Due to the smaller 
input sample volume, there is a risk of false negatives with DBS(21).  Sensitivity of DBS viral load was 
found to be 78–100% compared to plasma at viral load below 1000 copies/ml, but this increased to 
100% at a threshold of 5000 copies/ml(21). The systematic review showed that specificity was close to 
100% at DBS viral load above 5000 copies/ml, and this threshold would be the most reliable for 
predicting true virological failure using DBS(21).   
 
In an update on the technical and operational considerations for implementing HIV viral load testing 
published by WHO in 2014 it is advised that all manufacturers of viral load assays should provide a 
protocol for DBS specimens and pursue regulatory approval for in vitro diagnostics using DBS(17).  It 
also indicates that the performance of DBS for HIV viral load testing varies by platform compared 
with plasma(17).   
 
The optimal threshold for defining virological failure and for switching cART regimens has not been 
established(5).  Most standard viral load assays have good diagnostic accuracy at 1000 copies/ml 
(Table 2)(5, 30).  However, the sensitivity of DBS for viral load determination at this threshold may be 
reduced(5).  The 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection recommend that programmes relying on DBS for viral load assessment 
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should consider a higher threshold (3000–5000 copies/ml) until sensitivity at lower thresholds is 
established(5).  In the updated 2016 WHO consolidated guidelines, it is now recommended to use a 
threshold of 1000 copies/ml to determine virological failure using DBS, based on a systematic review 
of 43 studies that compared DBS to plasma showing acceptable sensitivity and specificity (Table 3)(6).  
However this is stated as a conditional recommendation with low quality evidence(6).  Modelling 
suggests that if DBS viral load testing can be performed with reasonable sensitivity and specificity 
(>85%) then costs and outcomes are similar to plasma based testing(6).  An important limitation is 
that the majority of studies included in the review used venous whole blood specimens prepared in 
the laboratory using precision pipettes to dispense the blood onto the filter paper rather than based 
on specimens obtained in clinical settings(6). 
 
Table 2.  Commercially available HIV viral load assays(30) 
 
Assay Nucleic acid 
extraction 
specificity 
Detection 
method 
specificity 
LOQ plasma 
(copies/ml) 
LOQ DBS 
(copies/ml) 
Abbott  
RealTime HIV-1 
Iron oxide 
microparticle 
capture - RNA 
selective 
Real time PCR – 
non-specific 
40 500-800 
Artus HI Virus-1 
RG 
Total nucleic acid Real time PCR – 
non-specific 
60 Unknown 
Biocentric 
Generic HIV 
Charge Virale 
Qiagen extraction 
– total nucleic 
acid 
Real time PCR – 
non-specific 
188-300 740-5000 
BioMérieux 
NucliSENS EasyQ 
HIV-1 v2.0 
Boom method – 
total nucleic acid 
NASBA – RNA 
specific 
25 800 
Roche COBAS 
Taqman HIV-1 
v2.0 
Magnetic glass 
particle 
purification – 
total nucleic acid 
Real time PCR, 
dual probe –  
non-specific 
20 400 
Versant HIV-1 
RNA 1.0 
Total nucleic acid Kinetic PCR 37 866 
Commercially available assays for HIV viral load are listed in the following table with their nucleic acid 
extraction specificity, detection method specificity and limit of quantification in plasma and DBS.  LOQ = limit 
of quantification. 
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Table 3.   Performance characteristics of DBS HIV viral load for detection of virological failure(6, 17) 
 
Assay  Sensitivity 
 (mean and 95% CI) 
Specificity 
(mean and 95% CI) 
N 
Abbott  
RealTime HIV-1 
95% 
(82-99%) 
92% 
(79–97%)  
 
1529 
Biocentric Generic  
HIV Charge Virale 
95%  
(71-99%) 
55% 
(35-74%) 
531 
BioMérieux NucliSENS 
EasyQ HIV-1 v2.0 
84% 
(79-89%) 
95% 
(86-98%) 
1062 
Roche COBAS TaqMan 
HIV-1 v2.0 (free virus 
elution protocol) 
85% 
(77-91%) 
94% 
(85-98%) 
229 
Roche COBAS TaqMan 
HIV-1 v2.0 (SPEX 
protocol) 
99% 
(97-100%) 
44% 
(18-74%) 
2314 
Versant HIV-1 RNA 1.0 91% 
(69-98%) 
 
88% 
(75-94%) 
144 
Data on performance characteristics for commercially available molecular HIV viral load assays using DBS 
compared with plasma at 1000 copies/ml cut-off.  Pooled estimates of sensitivity and specificity based on 
published data up to June 2015
(6)
.  95% CI = 95% confidence interval.  N = number of samples. 
 
In conclusion, various strategies have been proposed to expand access to HIV viral load testing due 
to the restrictions from plasma based testing.  The most promising is whole blood testing in the form 
of DBS or POC tests.  DBS is currently recommended by WHO in remote areas, and has been 
evaluated in several studies and found to be cost effective and performs reasonably.  Novel POC 
technologies are also anticipated as a means to decentralise testing and facilitate prompt clinical 
decision making to detect virological failure.  However whole blood viral load presents its own 
inherent challenges in terms of reduced sensitivity and specificity and therefore interpretation.  The 
reduced sensitivity of DBS compared to plasma due to lower input volume does not negatively 
impact on the detection of virological failure as the limit of detection of most assays evaluated is 
below 1000 copies/ml.  The major issue with whole blood viral load testing is the reduced specificity 
leading to upward misclassification.  A higher threshold should be used to avoid misclassification.  
The precise threshold to be used is likely to be different for each assay and patient, depending on 
assay methodology and patient factors such as CD4 count, HIV DNA and intracellular RNA copy 
number(30).  Methods may be required that increase the specificity of the test such as DNAse 
treatment, RNA specific nucleic acid extraction or detection, and removal of cellular components 
before extraction(30).  The optimum threshold for the correct classification of virological failure in 
whole blood requires further studies. 
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Chapter 2:  Manuscript 
1. Background 
The global HIV/AIDS pandemic is undoubtedly one of the most significant public health challenges 
faced in our time with approximately 36.7 million people currently infected(1, 2).  The brunt of the 
disease burden lies in sub-Saharan Africa where disadvantaged socioeconomic circumstances have 
led to reduced access to health care and quality of life.  However tremendous gains have been 
achieved in the last decade especially in increasing treatment coverage to advance the UNAIDS 90-
90-90 goal, whereby 90% of people living with HIV know their HIV status, 90% of people who know 
their HIV-positive status are accessing treatment and 90% of people on treatment have suppressed 
HIV viral loads(3). 
 
HIV viral load is an essential part of routine monitoring of HIV infected patients on combination 
antiretroviral therapy (cART) as it is a measure of virological suppression, adherence and will identify 
virological failure(4).  Plasma HIV viral load is the current universal standard of care.  Virological 
failure as defined by the World Health Organisation (WHO) is plasma HIV RNA > 1000 copies/ml on 
two consecutive viral load measurements within a three month interval with adherence support 
after at least six months of cART use(5).  Viral load should be tested at 6 months after cART initiation 
and then annually(4).   
Although HIV viral load is recommended as the gold standard for HIV treatment monitoring, many 
low and middle income countries have limited access(6).  With an expanding number of HIV infected 
patients on cART, there is an increased demand and workload on laboratories in producing HIV viral 
load results accurately and timeously.  Currently HIV viral load testing by real time PCR is complex, 
expensive and  restricted to centralised laboratories with trained personnel and infrastructure(7).   In 
rural or remote areas, timely plasma separation and transportation to testing laboratories is a major 
barrier to the access of HIV viral load testing.   Sampling requires collection of a venous whole blood 
sample that is stable at room temperature for only up to six hours and therefore requires cold chain 
storage and has to be centrifuged prior to testing(8).  Sample transport networks are often not 
available or not well functioning resulting in significant delays in processing of samples(9). 
 
There exists a burgeoning need for cost effective methods to improve access and implement scale 
up of viral load testing.  Potential solutions explored are the utilization of whole blood HIV viral load 
testing in the form of dried blood spot (DBS) testing or direct use of whole blood on point of care 
(POC) testing platforms which would simplify the whole process of sample collection, storage and 
transportation(10).   
 
In South Africa DBS is routinely used for infant HIV diagnostic PCR testing(11). DBS is simple to collect 
and prepare and stable at room temperature therefore easy to transport with no need for cold chain 
or worry about transportation delays.  Use of DBS would reduce the costs incurred from materials 
and waste disposal of standard blood collection and the need for a skilled phlebotomist(12). 
 
The routine use of POC devices for HIV diagnostics such as the lateral flow rapid HIV test has 
facilitated the HIV care and testing programme so that patients are counselled, tested and provided 
HIV test results all at the same visit thus fundamentally improving access to HIV testing and care.  
POC HIV viral load assays will facilitate earlier identification of treatment failure(13).  POC viral load 
testing could form part of a tiered implementation model that includes both POC testing and 
different tiers of laboratory testing to ensure access for the entire national population(13).   
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However there is a paucity of studies that have compared whole blood HIV viral load results across 
platforms.  There are various commercial HIV viral load assays and real time PCR platforms available 
with differences in nucleic acid extraction, PCR target, amplification and detection methodologies 
hence the difficulty arises in directly comparing these different platforms head to head.  
Interpretation of whole blood HIV viral load is also complex especially at low viral loads(14).  Previous 
studies have shown reduced specificity due to cell associated HIV nucleic acids as well as reduced 
sensitivity due to smaller sample volumes used in comparison to plasma(15).   
Due to the limited data available with a demand identified for alternative simpler methods of HIV 
viral load testing strategies and a need for comparative studies of test performance of various 
commercial viral load assays using whole blood, we embarked on this study to evaluate whole blood 
HIV viral load testing using DBS on all the commercially available platforms in our setting as well as 
on a POC device.  Correlation with plasma HIV viral load as gold standard and correct classification of 
virological failure were used to evaluate performance.   This evaluation will help determine the 
clinical utility of using whole blood HIV viral load in the monitoring of patients on cART in resource 
limited settings. 
 
2. Methods 
 
2.1 Study design and population: 
This was a laboratory-based cross sectional study comparing different whole blood HIV viral load 
methodologies through testing of routine clinical HIV plasma viral load sent to Groote Schuur 
Hospital, Virology Laboratory, National Health Laboratory Service.   Whole blood HIV viral load 
methodologies were evaluated on four assays namely Alere q HIV-1/2 point of care device, Abbott 
RealTime HIV-1 DBS original open-mode protocol and updated new prototype protocol, and Roche 
CAP/CTM HIV-1 v2.0 DBS free virus elution (FVE) protocol (Table 4). The study population from 
which the samples were selected comprised of patients from the South African public health care 
sector in the Western Cape, the majority of whom are on cART.  Clinical and laboratory factors that 
might have played a role in the discrepancy between various HIV viral load methodologies were 
retrieved from the laboratory information system.  These parameters included age, gender, CD4 
count current and nadir, treatment history, duration on cART and viral load history.  
 
2.2 Sampling and Procedures 
Plasma HIV viral load was used as the gold standard and was performed using Abbott RealTime HIV-
1 (Abbott Laboratories, Chicago, USA) according to the manufacturer’s instructions(16).  To ensure 
coverage across the viral load spectrum, we selected plasma viral load results to include at least 50 
specimens from each of four categories: lower than detectable limit, detectable – 1000 copies/ml, 
1000 – 10,000 copies/ml and > 10,000 copies/ml. Parallel whole blood HIV viral load testing was 
performed using whole blood samples submitted for CD4 testing taken at the same time as the 
plasma HIV viral load sample.  25ul of whole blood from the CD4 count sample was used for HIV viral 
load testing on Alere q HIV-1/2 point of care device, at the same time the DBS was prepared by 
applying 75ul of whole blood to each individual spot on a Whatman 903 filter-paper card.  This was 
done within 72 hours of sample receipt to ensure no delays that could have resulted in poor quality 
degraded EDTA sample.  The DBS cards were kept on racks to dry overnight away from sunlight, and 
once dry packed with silica gel dessicant in sealed plastic bags to protect from humidity.  DBS 
preparation and all testing were performed in the laboratory. Testing was performed in 
collaboration with another viral load reference centre, HIV Molecular Laboratory at Charlotte 
Maxeke Johannesburg Academic Hospital.  Abbott updated protocol and Roche FVE protocol were 
tested by this laboratory. 
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2.3 Ethics 
Ethics approval for the study was received from the Human Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town (HREC REF: 819/2014). 
 
2.4 Analysis 
Data collected was entered in tabulated form in Microsoft Excel 2007.  Linear correlation of the 
plasma and whole blood viral load comparison and Bland-Altman plots were plotted and analysed 
using Microsoft Excel 2007, while receiver operating characteristic (ROC) curve analysis, sensitivity, 
specificity, positive predictive value, negative predictive value and concordance were calculated 
using Stata version 11. Proportions of correct classification of virological failure using the plasma 
threshold of 1000 copies/ml and overall correlation with gold standard were used for evaluating 
each method’s performance.  Viral load results are reported in copies/ml or log10 transformed 
copies/ml. 
Table 4.  HIV viral load test methods 
 
Table 4 provides a list of the assays evaluated in the study: their sample type, volume used and reportable 
range in copies/ml.  For details of each assay methodology, refer to cited references. 
 
 
 
 
 
 
 
 
 
 
 
 
Method 
 
Assay (Abbreviation) 
 
Sample 
Type 
 
Sample 
Volume 
 
Reportable Range 
copies/ml 
1 Standard of care:  Abbott RealTime HIV-1(16) 
(Plasma VL) 
Plasma 
Gold 
standard 
600ul or 
200ul 
40 – 10 million  
(600ul) 
150 - 10 million 
(200ul) 
2 Point-of-care:  Alere q HIV-1/2 (17, 18)   
(Alere q) 
EDTA whole 
blood 
25ul 2491 – 10 million 
3 Abbott RealTime HIV-1 original ‘open 
mode’ protocol(19)   (Abbott original) 
DBS 2 x 75ul 
spots 
550 - 10 million 
4 Abbott RealTime HIV-1 updated new 
prototype protocol (20) (Abbott updated) 
DBS 1 x 75ul spot 1000 - 10 million 
5 Roche COBAS AmpliPrep/COBAS TaqMan 
HIV-1 Test v2.0  -  free virus elution 
protocol(21)   (Roche FVE) 
DBS 1 x 75ul spot 400 – 10 million 
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3. Results 
 
3.1 Proportion of plasma viral load categories: 
299 samples that were tested with the standard of care plasma VL were selected across a wide 
quantitative range, of which 94 (32%) were below detectable limit, 52 (17%) between 40-1000 
copies/ml, 52 (17%) between 1000-10,000 copies/ml, 53 (18%) between 10,000-100,000 copies/ml 
and 48 (16%) >100,000 copies/ml.     
 
3.2 Patient demographics data (Table 5): 
199 samples were from females and 100 were from males.  Median age of patients was 35 years 
(IQR 28-41).  21/297 (7%) of samples were from children (<= 12 years old) and 276/297 (93%) from 
adults.  The median CD4 count was 417 x 106/l (IQR 220-568).  The median plasma viral load was 
3.03 log10 copies/ml (IQR LDL - 4.57).  65% of patients were on 1
st line cART regimens and 12% were 
on 2nd line cART regimens.  22/299 (7%) of samples were pre-initiation cART viral loads and 48/299 
(16%) had no treatment history available on the laboratory information system.  Out of the 
remaining 229 patients, 83 (36%) had a past history of virological failure with one or more plasma VL 
>1000 copies/ml and 15 (7%) had no previous plasma VL on the laboratory information system. 
 
Table 5.  Patient demographics 
 
Patient demographics data N = 299  
 
Male 
Female 
N = 100 (33%) 
N = 199 (67%) 
Median age (range) 35 (39 days – 60 years old) 
Median CD4 count (range)  417 (4 – 2231 x 106/l) 
cART: 
1st line 
2nd line 
 
N = 194 (65%) 
N = 35 (12%) 
Past history of virological failure 
No previous plasma VL  
N = 83/229 (36%) 
N = 15/229 (7%) 
 
Median age of the study population was 35 years old, with majority female (67%), and on 1
st
 line cART (65%), 
and median CD4 count was 417 x 10
6
/l.  1
st
 line cART regimen consisted mainly of FDC (fixed drug combination) 
of TDF (tenofovir), 3TC/FTC (lamivudine/emtricitabine) and EFV (efavirenz) while 2
nd
 line cART regimens 
comprised AZT (zidovudine) or TDF + 3TC + lopinavir/ritonavir.  Of those with a previous viral load, 36% had a 
past history of virological failure with a plasma VL > 1000 copies/ml. N = number. 
 
3.3 Overall correct classification of virological failure (Fig. 1): 
Alere q, Abbott original, Abbott updated, and Roche FVE correctly classified virological failure in 
61%, 89%, 87% and 76% of all samples tested respectively.  Alere q, Abbott original and Abbott 
updated demonstrated over-quantification compared to plasma resulting in upward misclassification 
in 39%, 10% and 8% of all samples tested respectively.  Downward misclassification was seen in 1%, 
5% and 24% of all samples tested by Abbott original, Abbott updated and Roche FVE respectively.  
There was no downward misclassification by Alere q.   
 
18 
 
Fig.1 Percentage correct classification, downward misclassification and upward misclassification   
of virological failure by each of the whole blood assays compared to plasma 
 
Correct classification of virological failure was best by Abbott original and updated at 89% and 87% 
respectively, followed by Roche FVE at 76% and Alere q at 61%.  Upward misclassification which is 
misclassifying as virological failure when plasma VL is <1000 copies/ml, was evident by Alere q, Abbott original 
and updated at 39%, 10% and 8% respectively.  Downward misclassification which is not detecting virological 
failure when plasma VL is >1000 copies/ml, was mostly demonstrated by Roche FVE at 24%, with none by 
Alere q, and 1% and 5% of all samples by Abbott original and updated. 
           
3.4 Correct classification according to plasma VL categories: 
The performance varied across plasma VL categories (Table 6, Fig.2 and 3). 
3.4.1 Plasma VL lower than detectable limit (LDL): 
When plasma VL was LDL, correct classification of virological failure was 22%, 87%, 89% and 100% by 
Alere q, Abbott original, Abbott updated, and Roche FVE respectively.  Over-quantification of viral 
load resulting in upward misclassification was significant by Alere q at 78% (73/94) when plasma VL 
was LDL, and moderate by Abbott original and updated at 13% (12/94) and 11% (10/94) respectively 
(Fig.2).  There was no upward misclassification by Roche FVE.  Mean log10 copies/ml difference 
between plasma VL and Alere q, Abbott original, Abbott updated and Roche FVE was -2.85 (95% CI -
3.15 – -2.55), -0.60 (95% CI -0.86 - -0.35), -0.82 (95% CI -1.10 - -0.54), and -0.46 (95% CI -0.67- -0.25) 
respectively (Fig.3). 
3.4.2 Plasma VL detectable-1000 copies/ml: 
Correct classification at this range was lowest for most test methods at 14%, 63%, 75% and 98% for 
Alere q, Abbott original, Abbott updated and Roche FVE respectively.  Upward misclassification was 
highest in this category for Alere q, Abbott original and updated.  Only one sample was upwardly 
misclassified by Roche FVE.  The mean log10 copies/ml difference between plasma VL and Alere q, 
Abbott original, Abbott updated and Roche FVE was -0.94 (95% CI -1.31 - -0.57), 0.81 (95% CI 0.37 - 
1.25), 0.14 (95% CI -0.23 – 0.51), and 1.10 (95% CI 0.75 - 1.44) respectively (Fig.3).  Due to the 
greatest variability in this category, we performed further analysis using plasma VL of 400 copies/ml 
as a cut-off, to assess if there was a difference above 400 copies/ml indicative of impending 
virological failure, but there was no difference. 
3.4.3 Plasma VL 1000-10,000 copies/ml: 
Above plasma VL of 1000 copies/ml, Alere q showed 100% correct classification of virological failure 
demonstrating 100% sensitivity (Fig.2a).  Abbott original and updated correctly classified 94% and 
75% of samples respectively with downward misclassification in 6% and 25% respectively.  Roche 
FVE showed 0% sensitivity at this range by significant under-quantification of viral load resulting in 
failure of detecting virological failure in any of the plasma VL samples (0/50) tested at this range 
(Fig.2d).  Mean log10 copies/ml difference between plasma VL and Alere q, Abbott original, Abbott 
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updated and Roche FVE was -0.54 (95% CI -0.65 - -0.43), -0.15 (95% CI -0.34 – 0.05), 0.19 (95% CI 
0.02-0.37), and 1.30 (95% CI 0.99-1.60) respectively (Fig.3). 
3.4.4 Plasma VL >10,000 copies/ml: 
Excellent correlation above 10,000 copies/ml was observed for Alere q, Abbott original and updated 
with correct classification of virological failure at 100%, 100% and 99% respectively (Fig.2).  Roche 
FVE demonstrated better sensitivity at this range with correct classification of virological failure in 
80% (76/95) of samples tested and downward misclassification in 20% (19/95) of samples tested.  
Under-quantification by Roche FVE at this plasma VL stratum ranged from LDL – 2.96 log10 copies/ml 
(median = 2.67).  The mean log10 copies/ml difference between plasma VL and Alere q, Abbott 
original, Abbott updated and Roche FVE was -0.09 (95% CI -0.14- -0.03), -0.12 (95% CI -0.16 - -0.86), 
0.27 (95% CI 0.21-0.34), and 1.52 (95% CI 1.38-1.67) respectively (Fig.3). 
 
Table 6: Percentage of correct classification of virological failure by whole blood testing methods 
according to plasma VL categories 
 
 
Plasma VL 
 
LDL  
 
Detectable - 1000 
copies/ml 
 
1000-10,000 
copies/ml 
 
>10,000 
copies/ml 
N= 94 52 52 101 
 
Alere q 
 
22% 
 
14% 
 
100% 
 
100% 
 
Abbott  
original 
 
87% 
 
63% 
 
94% 
 
100% 
 
Abbott 
updated 
 
89% 
 
75% 
 
75% 
 
99% 
 
Roche FVE 
 
100% 
 
98% 
 
0% 
 
80% 
The performance of each whole blood assay differs according to the plasma VL category.  Alere q showed 
100% sensitivity above plasma VL of 1000 copies/ml, however below this level there was over-quantification 
resulting in upward misclassification in 78% of the plasma VL that were LDL and 86% in the detectable-1000 
copies/ml category.  For Abbott original and updated, sensitivity was best above 10,000 copies/ml, there was 
6% and 25% downward misclassification in the 1000-10,000 copies/ml category, and there was 37% and 25% 
upward misclassification in the detectable-1000 copies/ml category as well as 13% and 11% upward 
misclassification in the LDL category. Roche FVE demonstrated the opposite performance with reduced 
sensitivity of 0% in the 1000-10,000 copies/ml category.  Roche FVE had the best specificity of 100% when 
plasma VL was LDL and 98% in the detectable-1000 copies/ml category.  Correct classification was best for all 
methods at >10,000 copies/ml. 
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Fig.2 Correlation plots between plasma VL and each of the whole blood assays in log10 copies/ml 
 
 
Correlation plots between plasma VL and 2a) Alere q - R
2
= 0.46.  Correlation was good above plasma VL of 3 
log10 copies/ml, resulting in 100% sensitivity in detecting virological failure.  However below plasma VL of 3 
log10 copies/ml, there was significant overestimation with upward misclassification in 117/145 (81%) of 
samples by Alere q. 2b) Abbott original – had the best overall correlation with plasma VL (R
2
 = 0.76).  There 
was linear correlation above plasma VL of 3 log10 copies/ml.  Below plasma VL of 3 log10 copies/ml there was 
overestimation resulting in upward misclassification in 31/146 (21%) samples.  2c) Abbott updated – 2.9 log10 
has been used on plot for samples <1000 copies/ml (lower limit of quantification).  Correlation was similar to 
Abbott original (R
2
 = 0.72).  Correlation was excellent above 4 log10 copies/ml.  When plasma VL was 3-4 log10 
copies/ml, Abbott updated under-quantified 13/52 (25%) of samples resulting in downward misclassification.  
Below plasma VL of 3 log10 copies/ml there was upward misclassification in 23/145 (16%).  2d) Roche FVE - R
2
= 
0.62.  2.6 log10 has been used on plot for Roche FVE samples <400 copies/ml (lower limit of quantification).  
Below the plasma VL threshold of 3 log10 copies/ml, there was good correlation with Roche FVE correctly 
classifying 139/140 samples (99% specificity).   For plasma VL >3 log10 copies/ml, there was significant 
underestimation by Roche FVE especially between plasma 3-4 log10 copies/ml, with downward misclassification 
in 69/145 (48%). Results below the detectable limit are plotted as 0 for all the plots. 
 
 
 
2a 2b 
2c 2d 
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Fig.3 Bland Altman plots between plasma VL and each of the whole blood assays in log10 copies/ml 
 
      3a                                                                                    3b 
 
Overall mean log10 copies/ml difference between plasma VL and 3a) Alere q = -1.18 (95% CI -1.36 – -1.01).     
3b) Abbott original = -0.12 (95% CI -0.24 – 0.01).  3c) Abbott updated  = -0.11 (95% CI -0.24 – 0.02).   3d) Roche 
FVE = 0.78 (95% CI 0.63 – 0.93).  Note that viral load that was LDL was plotted as 0 on graph, <1000 copies/ml 
for Abbott updated was plotted as 2.9 log10, and <400 copies/ml for Roche FVE was plotted as 2.6 log10. 
3.5 Evaluation of clinical and laboratory factors associated with discrepancy between plasma and 
whole blood viral load: 
Among patients who were virologically suppressed, we analysed for clinical and laboratory factors 
that could potentially contribute to the over-quantification by whole blood viral load.  Data was 
retrieved from the laboratory information system which in 22/128 (17%) of current plasma VL<400 
copies/ml were missing or incomplete.  We assessed for history of virological failure especially 
recent (in the last 3-6 months) in those who had a current plasma VL <400 copies/ml.  In those 
patients with current plasma VL <400 copies/ml, there was no difference in median CD4 count in 
those who had a history of virological failure (median CD4 count = 431) and those with no history of 
virological failure (median CD4 count = 524).  There was also no difference in whole blood viral load 
in patients who had a history of virological failure and those who didn’t among the plasma 
virologically suppressed.  Median whole blood VL when plasma VL was < 400 copies/ml was 3.51 
log10 copies/ml in patients with no history of virological failure and 3.40 log10 copies/ml in patients 
with history of virological failure for Alere q.  Median whole blood VL when plasma VL was < 400 
copies/ml was LDL in both patients with history of virological failure and with no history of 
virological failure for Abbott original and updated and Roche FVE. 
 
3c 3d 
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Among patients with current plasma VL<400copies/ml, 14/105 (13%) had a past history of virological 
failure.  There was 71% upward misclassification rate by Alere q among those with past history of 
virological failure, while there was 84% upward misclassification among those with no history of 
virological failure (chi = 1.20).  Therefore past history of virological failure did not affect the upward 
misclassification by Alere q. 
 
We assessed for an association between CD4 count and upward misclassification in whole blood 
when plasma VL was <1000 copies/ml.  For Alere q there was no difference in median CD4 count of 
correctly classified samples and upwardly misclassified samples of 524 and 512 respectively (Fig. 4a).  
The same was also noted for Abbott original of median CD4 count of 517 for correctly classified 
samples and 494 for upwardly misclassified samples (Fig.4b). 
 
Fig.4 CD4 count according to correct classification and upward misclassification of virological 
failure when plasma VL <1000 copies/ml 
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No difference in the median CD4 count was noted between correctly classified and upwardly misclassified 
samples for both 4a) Alere q and 4b) Abbott original. 
 
3.5 Receiver operating characteristic (ROC) curve analysis (Fig.5): 
ROC curve analysis provided the optimum threshold for classification of virological failure for each 
whole blood method.  For the samples tested, 9249 copies/ml (3.97 log10) provided the best overall 
classification of 85% for Alere q with a sensitivity of 82% and a specificity of 89%.  2697 copies/ml 
(3.43 log10) provided the best overall classification of 94% for Abbott original with a sensitivity of 94% 
and a specificity of 93%. For Abbott updated, 1134 copies/ml (3.07 log10) provided the best overall 
classification of 88% with a sensitivity of 90% and a specificity of 86%. For Roche FVE, 400 copies/ml 
(2.60 log10) provided the best overall classification of 82% with a sensitivity of 92% and a specificity 
of 73%. 
 
 
 
 
 
4a 4b 
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Fig.5 ROC curve analysis of the whole blood test methods using the threshold of 1000 copies/ml 
for virological failure 
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ROC curve analysis for 5a) Alere q shows area under ROC curve = 0.92 (95% CI 0.89-0.95), 1419 copies/ml (3.15 
log10) and 44062 copies/ml (4.64 log10) provided 100% sensitivity and 100% specificity respectively.                 
5b) Abbott original area under ROC curve = 0.98 (95% CI 0.96-0.99), 974 copies/ml (2.99 log10) and 34025 
copies/ml (4.53 log10) provided 99% sensitivity and 100% specificity.  5c) Abbott updated area under ROC curve 
= 0.95 (95% CI 0.93-0.97), 999 copies/ml (2.99 log10) and 5995 copies/ml (3.78 log10) provided 99% sensitivity 
and 100% specificity. 5d) Roche FVE area under ROC curve = 0.90 (95% CI 0.87-0.94), 400 copies/ml (2.60 log10) 
and 2134 copies/ml (3.33 log10) provided 92% sensitivity and 100% specificity.  
4. Discussion 
The utilization of whole blood viral load testing offers an attractive solution to the scale up and 
widespread implementation of HIV viral load monitoring in resource limited settings.  As access 
increases, patients will be routinely monitored and virological failure will be detected and treatment 
switched earlier, with lower accumulation of drug resistance mutations, improved quality of life and 
lower rates of acquired and transmitted drug resistance.  Viral load informed differentiated cART 
care using DBS  was found to be cost effective in sub-Saharan Africa in a modelling study for 
sustainable HIV treatment(10).   
 
However whole blood viral load testing presents its own challenges in terms of interpretation of 
whole blood viral load which measures intracellular HIV RNA and/or proviral DNA in addition to 
extracellular HIV RNA that is measured from plasma.  This is a potential cause of overestimation of 
whole blood viral load in comparison to plasma VL.  Another limitation is the use of smaller sample 
5a 5b 
5c  5d 
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volumes for DBS and POC testing platforms in comparison to plasma which can lead to reduced 
sensitivity.  Previous studies have mainly evaluated DBS using a single methodology in comparison to 
plasma using the threshold of 1000 copies/ml. 
 
In our study we evaluated whole blood HIV viral load using different platforms and methodologies 
for testing as a comparison to plasma VL categories and to gauge the performance using the 
recommended WHO threshold of 1000 copies/ml for virological failure.  The key finding highlighted 
in our study is the great variability between each of the methods evaluated.  The differences are 
most likely attributed to various factors such as input volume used in each assay, sample 
treatment/processing (DBS versus fresh blood samples versus free virus elution), extraction (RNA 
selective, total nucleic acid extraction), amplification target and detection methods which are 
different for each of the platforms tested, and software cutoff algorithm is not standardized. 
Above plasma VL of 1000 copies/ml, classification of virological failure was good by three of the 
whole blood viral load methods:  Alere q, Abbott original and updated.  There was excellent 
classification of virological failure by these methods above plasma VL of 10,000 copies/ml.  However, 
the opposite was demonstrated by Roche FVE of reduced sensitivity resulting in significant 
downward misclassification of virological failure when plasma VL was 1000 – 10,000 copies/ml.  
Reduced sensitivity of DBS compared to plasma is caused by reduced input copy number from DBS 
related to limitations on the volume of blood per DBS (50-75ul) and number of DBS (usually not 
more than two) that can be subjected to nucleic acid extraction, reduced efficiency of nucleic acid 
extraction, and the presence of interfering substances in DBS (eg. haemoglobin) that can inhibit 
amplification or detection(14).  The reduced sensitivity of Roche FVE is presumably due to the free 
virus elution protocol used so that only cell free virus is measured in conjunction with the lower 
input volume of DBS.  Increasing the software correction factor or using two spots may help to 
improve the sensitivity. 
Greatest variability between the different testing methods was seen when plasma VL was 40-1000 
copies/ml resulting in upward misclassification of virological failure.  Reduced specificity of whole 
blood viral load compared to plasma results from cell associated HIV nucleic acids which may be in 
the form of proviral or unintegrated DNA, transcribed spliced/unspliced RNA or viral RNA in particles 
bound to cells such as platelets (14).   The relative contribution of each type of nucleic acid is likely to 
vary between patients depending on clinical parameters and treatment status(14).  There was 
significant over-quantification of whole blood viral load by Alere q, Abbott original and updated 
resulting in upward misclassification of virological failure.  When plasma VL was LDL, there was 
significant upward misclassification by Alere q.  There was also some over-quantification but to a 
much smaller degree by Abbott original and updated when plasma VL was LDL. Over-quantification 
is likely due to measurement of intracellular HIV RNA in whole blood in combination with 
extracellular HIV RNA, different extraction methods and amplification targets. The contribution of 
cell associated RNA and proviral DNA can add a “baseline” to the plasma VL detected below 3000–
5000 copies/ml (plasma RNA dominates the assay above 5000 copies/ml)(22). 
The Abbott HIV viral load method for extraction is selective for RNA therefore the over-
quantification is likely due to intracellular HIV RNA.  The extraction method for Alere q is also 
selective for RNA however the over-quantification is significantly greater, probably due to other 
differences such as assay target, detection methodology, in conjunction with cell associated HIV 
RNA.  The Roche FVE measures only extracellular HIV RNA similar to plasma therefore it 
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demonstrated the best specificity. Extraction methods that are selective for RNA have a closer 
correlation with plasma and include RNA-specific nucleic acid extraction, DNAse pretreatment to 
remove DNA, and virus particle elution(22).   
Therefore the threshold for whole blood virological failure needs to be raised in comparison to the 
plasma threshold of 1000 copies/ml to overcome reduced specificity.  However due to the variability 
between the different testing platforms, it would be difficult to utilize a uniform threshold across all 
platforms for whole blood virological failure.  Performing receiver operating characteristic curve 
analysis for each testing method helps to determine the optimum threshold for each method.  
However, the thresholds from our ROC curve analysis may be artificial due to the small sample size 
and does not take into account individual patient clinical differences. 
Our study is one of the preliminary studies evaluating POC Alere q viral load.  The advantages of POC 
Alere q are ease of use, minimal training required, small portable instrument with minimal reagents, 
closed system, very small sample volume required, built in controls, results in less than an hour, 
molecular detection and quantification of HIV-1 and HIV-2, low error rate, and excellent sensitivity 
for detection of virological failure as demonstrated in our study.  Disadvantages include cost per 
test, low throughput, and reduced specificity.   Another study recently published on POC Alere q viral 
load using finger-prick capillary whole blood samples in a primary health care centre in Mozambique 
also had similar results to ours albeit with better specificity – the sensitivity was 96.83% and the 
specificity was 47.8% using the threshold of 1000 copies/ml for virological failure(23).  They also 
suggested that a raised cut-off of 10,000 copies/ml is a better predictor of virological failure for Alere 
q(23). 
 
In a study evaluating DBS for virological failure by Sawadogo et al., they state that the WHO 
recommendations for DBS viral load monitoring should not treat different assay versions, types and 
RNA extraction methods used with DBS as homogeneous and that explicit recommendations for viral 
load testing with DBS for each of the prequalified viral load assay versions and types should be 
included, or recommendations should be further qualified until evidence for or against their use 
becomes conclusive(24). 
 
Our study clearly illustrates the differences with each of the different test methods for whole blood 
viral load and the difficulty assigning a uniform threshold for virological failure.  Solutions are 
required so that whole blood viral load monitoring can be implemented as routine testing in rural 
settings where the utilization of whole blood is the best practical alternative to plasma.  Possible 
solutions include:  the threshold for whole blood virological failure can be raised (>5000 copies/ml) 
to ensure optimum specificity (reduce upward misclassification) across different test methods, 
alternatively each whole blood test method would define its own threshold by ROC curve analysis 
(however this would be complicated on a programmatic level for HIV guidelines and 
implementation).  Further work needs to be done to harmonize or standardize the whole blood viral 
load methodologies such that a universal threshold with optimal sensitivity and specificity for 
virological failure can be used. 
 
The reduced sensitivity of DBS compared to plasma due to lower input volume does not negatively 
impact on the detection of virological failure as the limit of detection of most whole blood assays 
evaluated is below 1000 copies/ml.  The major issue with whole blood viral load testing is the 
reduced specificity leading to upward misclassification.  A higher threshold should be used to avoid 
misclassification. The precise threshold to be used is likely to be different for each assay and patient, 
depending on assay methodology and patient factors such as CD4 count, HIV DNA and intracellular 
26 
 
RNA copy number(14).   Methods may be required that increase the specificity of the test such as 
DNAse treatment, RNA specific nucleic acid extraction or detection, and removal of cellular 
components before extraction(14).  POC technologies are being developed that include an internal or 
external plasma separation step(23). 
 
Patient factors such as CD4 count and treatment status impact on HIV DNA and intracellular HIV RNA 
copy number.  In untreated patients or patients failing cART and as CD4 count declines, the HIV DNA 
and intracellular HIV copy number increases.  In our study no associations could be made with the 
discrepancy in whole blood testing methods with clinical and laboratory factors collected from the 
laboratory information system such as CD4 count and previous history of virological failure.  
However it was difficult to gather clinical information from the laboratory information system with 
many request forms being incompletely filled or no histories available. 
The prevalence of virological failure might impact on the utility of these assays.  For example, with a 
5% prevalence of virological failure Alere q has a positive predictive value (PPV) of only 6% and a 
negative predictive value (NPV) of 100%, if the prevalence is higher at 30% then the PPV is still low at 
35% and the NPV remains 100%.  Alere q has an excellent NPV to rule out virological failure but a 
positive result has a poor PPV and would need supplemental testing with a more specific test.  The 
other alternative that could be helpful especially in low prevalence settings would be to raise the 
threshold for virological failure for Alere q to 10,000 copies/ml, which according to our ROC curve 
analysis would improve specificity to 90% although reducing sensitivity to 80%.  Roche FVE has a PPV 
of 74% and NPV of 98% with a prevalence of 5%, and with a higher prevalence of 30% the PPV is 96% 
and the NPV is 83%.  In contrast to the other whole blood assays, Roche FVE has a better PPV and 
the NPV drops with increasing prevalence.  Roche FVE needs to increase sensitivity especially for use 
with high prevalence of virological failure.  Although the whole blood assays perform differently in 
comparison to each other, their unified strength is an excellent PPV above 10,000 copies/ml.  A 
result below this threshold would need additional testing, preferably repeating after a specified time 
period to monitor the viral load trajectory.  Assessing the utility of this approach would require 
collection of longitudinal data to monitor kinetics of whole blood viral load in patients on cART. 
Currently DBS seems to be the easiest option for increasing access and is also recommended by 
WHO.  Health care providers at primary health care facilities are already trained in collecting DBS as 
it is part of the HIV early infant diagnosis programme.  Centralised laboratories with high throughput 
will need to transition from plasma based testing to DBS, especially taking care to avoid 
contamination during DBS processing.  Pre-punched DBS cards are preferable which obviates the 
need of cutting spots.  As POC technologies become more accessible and affordable, it would be 
helpful to use in certain settings especially in remote areas where results are required swiftly to 
guide clinical decision making.  POC testing can serve as a complementary tool to expand access to 
viral load. 
Limitations of the study include plasma and whole blood viral load not tested simultaneously, DBS 
prepared in the laboratory using venipuncture blood and not in the health care facility, DBS and POC 
whole blood viral load performed in a controlled laboratory environment, difficulty collecting clinical 
information from the laboratory information system for analysis of clinical factors, whole blood HIV 
viral load testing methods are currently under research use and not being used for routine 
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diagnostics with individualized non-standardized protocols.  True performance in a real world setting 
may be more variable compared to our results. 
5. Conclusion 
Variability was noted between the different whole blood viral load assays. Alere q and Abbott 
original and updated had excellent sensitivity but had over-quantification below plasma VL of 1000 
copies/ml resulting in significant upward misclassification of virological failure. Roche FVE had 
excellent specificity however a significant proportion of plasma samples between 1000 – 10,000 
copies/ml were misclassified as virologically suppressed. Factors such as sample input volume, 
sample treatment/processing, sample extraction methods and amplification targets influences the 
ability to quantify whole blood viral load. Based on our study, Alere q and Abbott original and 
updated need to raise their whole blood threshold for virological failure in order to reduce upward 
misclassification and Roche FVE needs to achieve better sensitivity around its limit of detection. 
Receiver operating characteristic curve analysis will help to determine the optimum threshold of 
virological failure for each assay. 
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